Tenofovir
-
Subject Areas on Research
- Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.
- Acute renal failure after initiation of tenofovir disoproxil fumarate.
- Antiretroviral medications: adverse effects on the kidney.
- Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.
- Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.
- Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
- Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
- Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
- Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
- Design of tenofovir-UC781 combination microbicide vaginal gels.
- Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.
- Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.
- Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
- Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
- Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.
- FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
- Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
- Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
- Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
- Full depth measurement of tenofovir transport in rectal mucosa using confocal Raman spectroscopy and optical coherence tomography.
- Hepatitis B virus viral load and treatment decision.
- High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
- Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.
- Kidney disease in patients with HIV infection and AIDS.
- Label-Free Measurements of Tenofovir Diffusion Coefficients in a Microbicide Gel Using Raman Spectroscopy.
- Label-free analysis of tenofovir delivery to vaginal tissue using co-registered confocal Raman spectroscopy and optical coherence tomography.
- Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
- Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
- Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
- Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
- Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.
- Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
- Newer treatments for HIV in children.
- Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.
- Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP.
- Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
- Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
- Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.
- Preexposure prophylaxis for HIV infection among African women.
- Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
- Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
- Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery.
- Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
- Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
- Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
- Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya.
- Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
- Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
- Tenofovir alafenamide for HIV infection: is less more?
- The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
- The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.
- Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy.
- Vaginal deployment and tenofovir delivery by microbicide gels.